À propos
Experienced biotech executive with over twenty years spent in pharmaceutical…
Activité
2 k abonnés
-
Andy Parker a republié ceciAndy Parker a republié ceciOur Chief Executive Officer Andy Parker will be attending two upcoming healthcare conferences this September. Andy will attend the Wells Fargo Healthcare Conference in Boston, followed by the Cantor Fitzgerald Global Healthcare Conference in New York. If you are interested in learning more about Step Pharma's approach to CTPS1 inhibition and our data-driven 'pipeline in a product' strategy for dencatistat across essential thrombocythaemia, lymphoma and solid tumours, please reach out to connect. #CantorHealthcare #WellsFargoHealthcare #Oncology #DrugDevelopment #Biotech #Innovation
-
Andy Parker a republié ceciAndy Parker a republié ceciWe are excited to share that our CEO Andy Parker featured on the latest episode of Beyond Biotech, the podcast by Labiotech.eu, with host Dylan Kissane. Their discussion included: • How Andy’s career across pharmaceutical, biotechnology and VC organisations shaped his perspective on drug development • How dencatistat, our first-in-class CTPS1 inhibitor, targets one novel mechanism relevant across three indications, and how we are progressing a "pipeline in a product" strategy for our lead candidate • Where Step’s development strategy is heading, with dencatistat recently advancing into phase 2 in essential thrombocythaemia A big thank you to Dylan for hosting such an engaging conversation! Listen to the full episode here: https://lnkd.in/eVBUn-qT #Podcast #DrugDevelopment #Innovation #Biotech #Oncology
-
Andy Parker a partagé ceciIt was a pleasure to share Step Pharma's progress and plans with a room full of top US and European investors at the 10th Annual Venrock European Investor Tour in London this week. Many thanks to the co-hosts Meru Advisors and Bain Capital and to the sponsors TD Cowen, Stout and Davis Polk.
-
Andy Parker a republié ceciAndy Parker a republié ceciOur CEO Andy Parker is heading to San Diego for the BIO International Convention taking place from 22-25 June. Andy will be attending soon after our recent announcement that dencatistat, our investigational CTPS1 inhibitor, has advanced into a phase 2 trial for essential thrombocythaemia (ET), a rare clonal blood disorder which has seen no new treatments in decades. If you are attending BIO and are interested in learning more about Step Pharma’s data-driven ‘product in a pipeline’ strategy across ET, multiple solid tumours and blood cancers, please do reach out to connect. #BIO2026 #CancerResearch #Oncology #Innovation #DrugDevelopment
-
Andy Parker a republié ceciGreat to see this article by our VP, Clinical Operations, Maureen Higgins featured in Clinical Leader, highlighting how lean, highly collaborative teams can successfully deliver ambitious clinical development programs. Maureen shares insights from our experience advancing dencatistat across multiple indications while keeping patients, science, and operational excellence at the center of everything we do. Read the full article below. https://lnkd.in/ge4Q9CbbAndy Parker a republié ceciHaving the same number of clinical programs as team members might sound crazy, but for Step Pharma, it has become one of their biggest strengths. Here, the company's Vice President, Head of Clinical Operations Maureen Higgins shares how small can be mighty. https://lnkd.in/ge4Q9CbbOne Drug, Three Indications: How Small ClinOps Teams Manage Multi-Trial ExecutionOne Drug, Three Indications: How Small ClinOps Teams Manage Multi-Trial Execution
-
Andy Parker a republié ceciAndy Parker a republié ceciWe’re pleased to announce that our investigational first-in-class, highly selective, oral CTPS1 inhibitor, dencatistat, has advanced into a phase 2 clinical trial for essential thrombocythaemia (ET). ET is a rare clonal blood disorder characterised by overproduction of platelets and an increased risk of thrombosis. This key milestone follows encouraging results from our phase 1b trial which has enrolled participants across all ET mutation subtypes. The phase 2 trial, named VECTRA, will evaluate the safety, tolerability and efficacy of dencatistat, in up to 50 individuals with high risk ET across sites in the US, EU and UK. Read the full press release here: https://lnkd.in/eFN58B9W #ClinicalTrials #EssentialThrombocythaemia #ET #Haematology #Biotech #DrugDevelopment
-
Andy Parker a republié ceciAndy Parker a republié ceciVeille #Esante : 🏆 Les 14 lauréats de la santé de la promotion 2026 du French Tech " Next 40 & 120 " parmi les sociétés françaises les plus performantes de l’écosystème de la tech A la veille de VivaTech et comme à chaque promotion de La French Tech, je partage avec vous les lauréats du secteur de la santé & de la Healthtech - parmi les 120 sociétés françaises innovantes et à forte croissance ( les "scale-up" ) 🎯 Le "French Tech Next" est ouvert à tous les secteurs et à toutes les entreprises françaises qui développent des innovations qui transforment le quotidien en s'appuyant sur les technologies les plus stratégiques : IA, quantique, biotechn, ou encore aérospatial 📊 Les chiffres clés à retenir sur le French Tech Next40/120 : 💶 11,3 milliards € de chiffres d’affaires en 2025 📈 31% de croissance moyenne sur 1 an (hors entreprises DeepTech) 🟢 45% des entreprises sont rentables (hors entreprises DeepTech) 👭 46 000 emplois directs générés en France et dans le monde, dont 33 500 en France uniquement 🌎 97% des entreprises présentes à l’international 🏭 33 sites industriels en France pour 21% d’entreprises industrielles 💡 Les 120 entreprises du French Tech 120 sont sélectionnées sur la base d’une répartition paritaire : 6️⃣0️⃣ lauréats distingués par l’importance de leurs levées de fonds 6️⃣0️⃣ lauréats sélectionnés sur leurs revenus et leur dynamique de croissance 📋 Voici la liste où j'indique le nom de la société ainsi que son CEO : Next 4️⃣0️⃣ ( ≥ 20 M€ de chiffre d’affaires et ≥ 15 % de croissance annuelle moyenne sur 3 ans ) ✅ Alan ( Jean-Charles Samuelian-Werve ) ✅ AQEMIA ( Maximilien Levesque ) ✅ Doctolib ( Stanislas Niox-Chateau ) ✅ Hublo ( Antoine Loron ) ✅ MEDADOM ( Elie-Dan MIMOUNI ) ✅ Wandercraft ( Matthieu Masselin ) Next 1️⃣2️⃣0️⃣ : ✅ CorWave ( Louis de Lillers ) ✅ Moon Surgical ( Anne Osdoit ) ✅ Ouihelp ( Victor Sebag ) ✅ Resilience Care ( Jonathan Benhamou ) ✅ SparingVision ( Stephane Boissel ) ✅ Spore.Bio ( Amine Raji ) ✅ Step Pharma ( Andy Parker ) ✅ TISSIUM ( Christophe Bancel ) 🎓 La sélection du Next 40 a été réalisé par un comité de sélection composé des personnalités suivantes : 👉 Orianne Chenain, Cheffe de service de la compétitivité, de l’innovation et du développement des entreprises - Direction Générale des Entreprises 👉 Paul-François Fournier, Directeur Exécutif Bpifrance Innovation, Membre du comité Exécutif - Bpifrance 👉 Delphine de Dreux Brézé (d’Amarzit), CEO Euronext Paris, membre du Managing Board - Euronext 👉 Matthieu Eyriès, Executive VP & Managing Director - Capgemini Ventures 👉 Clément Gobet, Head of startups & scaleups Ecosystem - France Digitale 👉 Michel de Lempdes, Président France Deeptech 👏 Bravo à toutes les équipes de ces belles sociétés innovantes que nous connaissons bien dans notre média vidéo 👁️🗨️ L'Oeil de la E-santé et à la Mission de la French Tech qui met à l'honneur ces belles pépites ! 🔗 Je vous mets en commentaire la liste complète👇
-
Andy Parker a republié ceciAndy Parker a republié ceciWe are thrilled to have been selected for the 2026 French Tech 120 (FT120) programme, led by LaFrenchTech Paris-Saclay. This programme recognizes us as one the most promising French start-ups and is validation of our on-going commitment to addressing the need for innovative therapeutics for cancers and blood disorders. Through our efforts, we are advancing our first-in-class CTPS1 inhibitor, dencatistat, for essential thrombocythaemia, B and T cell lymphomas, and solid tumours. The FT120 programme grants us access to invaluable operational support from the Mission French Tech team enabling us to effectively deploy our resources and expedite our development pipeline. #FrenchTech120 #Innovation #CancerResearch #Oncology #DrugDevelopment
-
Andy Parker a republié ceciAndy Parker a republié ceciOur CEO Andy Parker, CSO Philip Beer, VP Head of Clinical Operations Maureen Higgins and Director Clinical Operations Carol M. are heading to Stockholm to attend the European Hematology Association (EHA) 2026 Congress, taking place from 11-14 June. At Step Pharma we are committed to advancing a new treatment option for patients living with complex blood cancers and disorders. Our first-in-class CTPS1 inhibitor, dencatistat, is progressing across clinical programmes in lymphoma and essential thrombocythaemia. We look forward to engaging with the haematology community to discuss the latest developments in the field. If you are attending the conference and would like to learn more, please reach out and connect. #EHA2026 #CancerResearch #Oncology #Innovation #DrugDevelopment
Andy Parker a commenté un post
11 mois
Congrats Pierre and team. A fantastic achievement.
Andy Parker a répondu à un commentaire
1 ans
Gary Allenby small world. My two sons were at the wedding - DJ and juggler. Hope all is well.
-
Andy Parker a aimé ceciAndy Parker a aimé ceciZealand Pharma is officially open in Cambridge, Massachusetts. Yesterday, we cut the ribbon on our new research hub at 35 CambridgePark Drive, now our primary U.S. address. The 53,600 sq ft site will take our research far beyond our core peptide expertise and into hybrid modalities, including biologics such as antibody-peptide conjugates with automation and advanced modeling methodologies built into how we work - from today. The hub is a central part of Metabolic Frontier 2030, our strategy to become a leader in obesity and metabolic health. It connects nearly 30 years of peptide science and data in Copenhagen with one of the strongest life science communities in the world. Thank you to MassBio, the City of Cambridge, Denmark in USA, Cambridge Chamber of Commerce (USA), and everyone who helped us get here. One company, two communities, working for the same purpose: to transform metabolic health, so millions can live without limits.
-
Andy Parker a aimé ceciAndy Parker a aimé ceciYesterday, 29 September, our CEO Jesús Martin Garcia took the stage at #BIOSPAIN2026 in Bilbao to present Peptomyc to investors, partners and industry leaders from across the global biotech community. In his pitch, Jesús shared how Peptomyc is pioneering the direct inhibition of MYC — one of the most sought-after and historically "undruggable" targets in oncology — and outlined the progress and next milestones of our clinical programme. We are grateful to the Biospain organisers for a well-run event and to everyone who joined the session and stopped by to connect. These conversations are key as we continue working to bring new treatment options to patients with cancer. #Peptomyc #MYC #Oncology #Biotech #DrugDevelopment #Bilbao
-
Andy Parker a aimé ceciIncredibly proud of what our CEO Ulrik Mouritzen and the entire Breye Therapeutics ApS team have achieved — raising €67.5 million is a tremendous milestone. Congratulations to all of you! A very warm welcome to all our new investors, joining us in this round co-led by Mission BioCapital and Novo Holdings., and a special thank you to Novo Holdings and Sound Bioventures for believing in Breye and supporting us from the very beginning. This is an exciting new chapter for Breye. Now it’s about turning this momentum into what truly matters: making a difference for patients !Andy Parker a aimé ceciBreye Therapeutics ApS has raised €67.5 million in an oversubscribed Series A financing. 🚀 The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital. The financing will support the advancement of danegaptide, a pioneering first-in-class oral treatment for Non-Proliferative Diabetic Retinopathy (NPDR), into a Phase II clinical trial. Diabetic retinopathy affects an estimated 130 million people globally and remains a leading cause of vision loss among working-age adults. Current treatments are typically reserved for later stages of disease and often require invasive injections directly into the eye, creating challenges for patients and long-term adherence. As an oral treatment for NPDR, danegaptide has the potential to provide a more convenient, non-invasive option for patients while addressing a significant unmet medical need. The proceeds will also support the continued development of Breye’s broader pipeline of retinal disease therapies, including its P2X7 receptor antagonist for intermediate age-related macular degeneration (iAMD) 👁️ This financing marks a major milestone in Breye’s mission to transform the treatment of retinal diseases and improve outcomes for patients worldwide. Congratulations to the team and all the investors involved 👏 🔗 Read the full press release here: https://lnkd.in/eZFSDwFH
-
Andy Parker a aimé ceciCongratulations to Ulrik Mouritzen and Breye Therapeutics ApS with the €67.5m Series A financing. This will allow us to conduct a clinical PoC, Phase 2 study to examine whether Danegaptide can prevent vision loss in patients with non-proliferative diabetic retinopathy, the most common cause of early blindness in the world. I also excited to welcome our new co-investors Mission BioCapital, Ljungström Family Office, EIFO, Innovestor, Catalyze Capital, Modi Ventures, and Pappas Capital, along with existing investor Sound Bioventures.Andy Parker a aimé ceciNovo Holdings has co-led Breye Therapeutics ApS' oversubscribed €67.5 million Series A, alongside new investor Mission BioCapital, to advance danegaptide – a first-in-class oral treatment for Non-Proliferative Diabetic Retinopathy (NPDR), an early stage of diabetic eye disease. Diabetic retinopathy affects some 130 million people worldwide. While existing treatments, injected directly into the eye, can help preserve vision in patients with late-stage disease, treatment options for those with early or moderate-stage NPDR remain limited. An oral therapy such as danegaptide would be complementary, helping more patients be treated. The funding will take danegaptide into Phase II trials and support Breye Therapeutics' wider pipeline in retinal disease. The round was also joined by existing investor Sound Bioventures, and new investors the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital.Novo Holdings · Novo Holdings co-leads Breye Therapeutics’ over-subscribed €67.5 million Series A financingNovo Holdings · Novo Holdings co-leads Breye Therapeutics’ over-subscribed €67.5 million Series A financing
-
Andy Parker a aimé ceciAndy Parker a aimé ceciToday we announced a key addition to our senior leadership team, with the appointment of Ramzi Benamar as our new Chief Financial Officer. Ramzi is accomplished biopharma executive with experience in capital formation, corporate strategy, M&A, operational scaling, and commercial launch preparation. His past leadership roles include serving as CFO for Bellus Health, Apnimed, DBV Technologies and Elucida Oncology. Welcome Ramzi! Read the full announcement here (https://lnkd.in/gPuHKuxC)
-
Andy Parker a aimé ceciI‘m happy to inform that I have started as CTO in a newly founded UK biopharmaceutical company. I’m leading the design and synthesis of antisense oligonucleotide targeting central mechanisms of inherited cardiomyopathies. We employ advanced new combinations and designs of chemical nucleotide modifications. We harness the massive learnings in RNA Therapeutics medicinal chemistry and design novel potent, specific and stable 5’th generation antisense oligonucleotides.
-
Andy Parker a aimé ceciAndy Parker a aimé ceciLooking forward to a stimulating meeting. #BIOMEU2026 #Biomarkers #PrecisionMedicine #CompanionDiagnostics https://hubs.la/Q04sVJf00
-
Andy Parker a aimé ceciAndy Parker a aimé ceciSeeing so many of the people who have supported JEITO from the very beginning gathered in Paris to celebrate our fifth anniversary was deeply moving. Entrepreneurs, managers, scientists, physicians, industry players, investors, partners, institutions, colleagues, friends and families. So many people who believed, committed and helped turn an idea into what Jeito is today. Five years ago, when we created Jeito, one question was constantly on my mind: What do we do with the time that separates suffering from a solution? As a physician, I had experienced that question at the bedside. As a researcher, I knew the extraordinary power of science, but also that turning an idea into a medicine takes time. Patients cannot always wait. Jeito was born from the conviction that the time separating suffering from a solution should never be accepted as inevitable, and that we have a responsibility to do everything we can to shorten that distance. I came to see that investment, when guided by expertise and purpose, could be one of the ways to do just that: help innovation move, accelerate and reach patients sooner. Not simply as finance, but as one of the ways we can act on time. I was also deeply grateful to President Emmanuel Macron for the special message he shared with us on this anniversary and for his support to innovation, particularly in healthcare, and his determination to strengthen, through Choose France, the attractiveness of France and Europe across all fields of cutting-edge innovation. Five years later, this evening was a moment to look at how far we have come but, even more importantly, to renew our commitment to what lies ahead. There are still patients waiting, diseases without solutions and extraordinary innovations to bring to life. Five years ago, we set out to help turn time into possibility. Today, our responsibility is to keep turning possibility into reality. Further and faster for patients.
-
Andy Parker a aimé ceciAndy Parker a aimé ceciWe are delighted to welcome Marino Garcia and Naimish Patel, M.D. to Agomab's Board of Directors. Marino and Naimish bring decades of leadership experience across biotechnology, drug development, corporate strategy, and company building. Their deep expertise and proven track records will be invaluable as we continue advancing our mission to develop transformative therapies for patients living with fibro-inflammatory diseases. We look forward to benefiting from their perspectives and partnering closely with them as we work to create long-term value for patients, clinicians, and shareholders. Welcome to the Agomab team, Marino and Naimish! #Agomab #AGMB #Biotech #Leadership #BoardOfDirectors #Fibroinflammation #DrugDevelopment #LifeSciences #Biotechnology